Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,503.45
(
-1.56%
)
US TECH 100
23,272.00
(
-1.89%
)
Dow Jones
45,540.44
(
-1.05%
)
Brent Oil
108.46
(
3.85%
)
Bitcoin
69,879.53
(
-0.03%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: isolution post# 534

Friday, 12/05/2003 3:39:34 PM

Friday, December 05, 2003 3:39:34 PM

Post# of 257262
Re: Oxigene competition:

I took a small position in OXGN this week, mainly because the valuation is so low.

As far as I know, the VTA candidates at AZN and AVE are not being tested in eye disease, and hence they do not pose as large a competitive threat as OXGN’s C4AP.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today